Hinduja Global Solutions (HGS) Q3 23/24 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 23/24 earnings summary
2 Nov, 2026Executive summary
Q3 operating revenue was ₹1,203.7 crore, up 7.6% YoY; operating EBITDA rose 39.9% to ₹115.1 crore, and PBT before exceptional items turned positive at ₹16.2 crore from a ₹28.4 crore loss.
Performance benefited from BPM and Digital Media growth, stronger Canada and offshore operations, and lower manpower costs; economic uncertainty continued to delay client decisions.
Financial highlights
Q3 total income was ₹1,295.1 crore, up 11.2% YoY; total EBITDA, including other income, was ₹206.6 crore, up 61.9% YoY.
Q3 PAT was ₹8.2 crore versus ₹51.6 crore a year earlier; the comparison reflected prior-year exceptional income of ₹32.9 crore and tax reversals.
9M operating revenue was ₹3,517.0 crore, up 2.4%; operating EBITDA rose 39.3% to ₹289.5 crore, while total EBITDA fell 1.4% to ₹602.6 crore.
9M PBT before exceptional items was ₹69.1 crore versus ₹155.8 crore; total PAT was ₹43.2 crore versus ₹308.7 crore.
Standalone Q3 operating revenue was ₹407.8 crore; continuing-operations loss after tax was ₹28.0 crore.
Outlook and guidance
No numerical FY25 guidance was provided; growth was expected to track traditional rates, with efforts to improve margins.
Priorities include scaling technology practices, applying AI and analytics to CX operations, and developing AI-led process management; GenAI and LLMs were identified as medium-term opportunities.
Growth plans include cross-selling, verticalized solutions, digital sales, strategic M&A, and investment in people and technology across cloud, analytics, GenAI and social care.
Sales strategy emphasizes managed services and industry-specific solutions; management cited an encouraging pipeline and new US and UK logos.
Latest events from Hinduja Global Solutions
- Q2 operating EBITDA rose 30% as cost discipline offset muted growth.HGS
Q2 23/24 - FY2024 operating EBITDA rose 45.8% as AI-led growth advanced amid unresolved tax-search exposure.HGS
Q4 23/24 - One-time costs pressured margins; healthcare-sale gain lifted PAT, with recovery expected from Q2.HGS
Q1 24/25 - UK and macro headwinds cut revenue as technology and AI initiatives advanced.HGS
Q2 24/25 - FY25 PAT included a healthcare-sale gain as strategy pivots to AI-led digital growth.HGS
Q4 24/25 - Q3 EBITDA margin reached 19% as AI-led growth advanced amid near-term revenue pressure.HGS
Q3 24/25 - Margin expansion and digital traction amid softer Q1 revenue.HGS
Q1 25/26 - FY26 EBITDA fell 20.1%; record wins and Project GANGA support growth prospects.HGS
Q4 25/26 - Revenue held broadly steady as continuing losses widened; client wins and Project GANGA advanced.HGS
Q1 26/27